NCT03041038View on ClinicalTrials.gov

The Efficacy and Safety of Secukinumab in Patients With Ichthyoses

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

August 31, 2020

Study Completion Date

August 31, 2020

Conditions
IchthyosisAutosomal Recessive Congenital IchthyosisLamellar IchthyosisCongenital Ichthyosiform ErythrodermaEpidermolytic IchthyosisNetherton Syndrome
Interventions
DRUG

Secukinumab

Anti IL-17A antibody

DRUG

Placebo

Trial Locations (2)

10029

Department of Dermatology Icahn School of Medicine at Mount Sinai, New York

60611

Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago

All Listed Sponsors
collaborator

Icahn School of Medicine at Mount Sinai

OTHER

lead

Northwestern University

OTHER

NCT03041038 - The Efficacy and Safety of Secukinumab in Patients With Ichthyoses | Biotech Hunter | Biotech Hunter